KimberlyLBlackwellMD

Oncology • Durham, NC

Associate Professor of Medicine, Duke University

Join to view full profile

Dr. Blackwell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Blackwell's full profile

Already have an account?

Office
Duke Medical Ctr
Durham, NC 27710
Is this information wrong?

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1997 - 2000
Duke University HospitalResidency, Internal Medicine, 1994 - 1997
Mayo Clinic College of MedicineClass of 1994

Certifications & Licensure

NC State Medical License 1995 - 2024

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2011-2013
Most Compassionate Doctor American Registry
Join now to see all

Clinical Trials

Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer Start of enrollment: 2006 Apr 01
Terminated
Phase 1
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain Start of enrollment: 2007 May 01
Terminated
Phase 2
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer Start of enrollment: 2007 May 01
Completed
Phase 2
Phase II Dasatinib Study in Advanced Breast Cancer Start of enrollment: 2007 Oct 01
Completed
Phase 2
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis Start of enrollment: 2007 Nov 01
Completed
Phase 1, Phase 2
Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease Start of enrollment: 2007 Jun 01
Completed
Phase 1
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer Start of enrollment: 2011 Aug 01
Terminated
Phase 2
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases Start of enrollment: 2012 Feb 01
Active, not recruiting
Phase 2
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer Start of enrollment: 2012 Jul 12
Completed
Phase 1, Phase 2
Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer Start of enrollment: 2012 Sep 21
Completed
Phase 1
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

25 citations
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly L. Blackwell, Melinda L. Telli, Michelle E. Melisko, Volker Möbus, Javier Cortes, Alberto J. Montero, Cyn...> ;NPJ Breast Cancer. 2021 May 20
15 citations
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022
Rachel A. Freedman, Rebecca Gelman, Nathalie Y. R. Agar, Sandro Santagata, Elizabeth C. Randall, Begoña Gimenez-Cassina Lopez, Roisin M. Connolly, Ian F. Dunn, Catheri...> ;Clinical Breast Cancer. 2020 Apr 1
378 citations
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled...
Sandra M Swain, David Miles, Sung Bae Kim, Young-Hyuck Im, Seock-Ah Im, Vladimir Semiglazov, Eva Ciruelos, Andreas Schneeweiss, Sherene Loi, Estefania Monturus, Emma C...> ;The Lancet. Oncology. 2020 Apr 1
12 citations
Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-n...
Gabriel N. Hortobagyi, Salomon M. Stemmer, H. A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch-Shimon, M. Campone, K. Petrakova, K. L. Blackwell, EP Winer, Wolfgan...> ;Annals of Oncology. 2019 Nov 1
10 citations
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer
John H. Strickler, Christel Rushing, Donna Niedzwiecki, Abigail B. McLeod, Ivy Altomare, Hope E. Uronis, S. David Hsu, S. Yousuf Zafar, Michael A. Morse, David Z. Chan...> ;BMC Cancer. 2019 Nov 1
58 citations
Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors.
Li Zhu, Jessica L. Narloch, Sayali Onkar, Marion Joy, Gloria Broadwater, Catherine Luedke, Allison Hall, Rim S. Kim, Katherine L. Pogue-Geile, Sarah Sammons, Naema Nay...> ;Journal for Immunotherapy of Cancer. 2019 Oct 18
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
Y Wu, M M Amonkar, B H Sherrill, J O'Shaughnessy, C Ellis, J Baselga, K L Blackwell, H J Burstein> ;Annals of Oncology. 2019 Jun 1
40 citations
Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study.
Erika J. Crosby, William R. Gwin, Kimberly L. Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, Terry Hyslop, Sungjin Kim, Andre Rogatko, ...> ;Clinical Cancer Research. 2019 May 1
14 citations
Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.
Maria J. Sambade, Grace Prince, Allison M. Deal, Dimitri G. Trembath, Megan Jean McKee, Amy Garrett, Kevin Keith, Juanita Ramirez, Bentley R. Midkiff, Kimberly L. Blac...> ;Breast Cancer Research and Treatment. 2019 Apr 23
220 citations
TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases
Rachel A. Freedman, Rebecca Gelman, Carey K. Anders, Michelle E. Melisko, Heather A. Parsons, Anne Cropp, Kelly Silvestri, Christine M Cotter, Kathryn P. Componeschi, ...> ;Journal of Clinical Oncology. 2019 Mar 12
10 citations
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Denise A. Yardley, Lowell L. Hart, Anne Favret, Sibel Blau, Sami Diab, Donald A. Richards, Joseph A. Sparano, J. Thad Beck, Paul Richards, Patrick J. Ward, Bhuvaneswar...> ;Clinical Breast Cancer. 2019 Feb 28
Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Sarah Sammons, Noah Kornblum, Kimberly L. Blackwell> ;Targeted Oncology. 2019 Feb 1
12 citations
Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer
Sarah Sammons, Noah Kornblum, Kimberly L. Blackwell> ;Targeted Oncology. 2019 Feb 1
12 citations
Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
Kimberly L. Blackwell, Khalil Zaman, Shukui Qin, K. Tkaczuk, Mario Campone, Daniel Hunt, Richard Bryce, Lori J. Goldstein> ;Clinical Breast Cancer. 2019 Apr 1
218 citations
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative a...
G N Hortobagyi, S M Stemmer, H A Burris, Y S Yap, G S Sonke, S Paluch-Shimon, M Campone, K Petrakova, K L Blackwell, E P Winer, W Janni, S Verma, P Conte, C L Arteaga,...> ;Annals of Oncology. 2018 Jul 1
3 citations
Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in the Diagnosis of Breast Cancer Thoracic Metastases and Detection of Receptor Discordance
A. Christine Argento, Daniel L Gilstrap, Scott Shofer, Kamran Mahmood, Kimberly L. Blackwell, Momen M. Wahidi> ;Journal of Bronchology & Interventional Pulmonology. 2018 Jul 1
30 citations
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
Aditya Bardia, Ayca Gucalp, Noashir DaCosta, Nashat Gabrail, Michael A. Danso, Haythem Ali, Kimberly L. Blackwell, Lisa A. Carey, Joel R. Eisner, Edwina Baskin-Bey, Ti...> ;Breast Cancer Research and Treatment. 2018 May 9
20 citations
Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.
Jeremy Force, Lynn Howie, Sara Abbott, Rex C. Bentley, P. Kelly Marcom, Gretchen Kimmick, Kelly Westbrook, Sarah Sammons, Michelle Parks, Donna L. Topping, Ryan O. Eme...> ;Clinical Breast Cancer. 2018 Oct 1
44 citations
The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
Kimberly L. Blackwell, Joseph Gligorov, Ira Jacobs, Chris Twelves> ;Clinical Breast Cancer. 2018 Apr 1
9 citations
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
Nadia Harbeck, Pere Gascón, Andriy Krendyukov, Nadja Hoebel, Sreekanth Gattu, Kimberly L. Blackwell> ;The Oncologist. 2018 Apr 1
16 citations
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in th...
Kimberly L. Blackwell, Pere Gascón, Andriy Krendyukov, Sreekanth Gattu, Y. Li, Nadia Harbeck> ;Annals of Oncology. 2018 Jan 1
5 citations
Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis
Ronnie L. Shammas, Eugenia H. Cho, Adam D. Glener, Luke P. Poveromo, Lily R. Mundy, Rachel A. Greenup, Kimberly L. Blackwell, Scott T. Hollenbeck> ;Journal of the American College of Surgeons. 2017 Dec 1
25 citations
Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.
Jessica L. Narloch, S. Harrison Farber, Sarah Sammons, Frances McSherry, James E. Herndon, Jenny K. Hoang, Fang-Fang Yin, John H. Sampson, Peter E. Fecci, Kimberly L. ...> ;Neuro-Oncology. 2017 Oct 1
134 citations
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.
Cynthia X. Ma, Ron Bose, Feng Gao, Rachel A. Freedman, Melinda L. Telli, Gretchen Kimmick, Eric P. Winer, Michael Naughton, Matthew P. Goetz, Christy A. Russell, Debu ...> ;Clinical Cancer Research. 2017 Oct 1
12 citations
Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer
Kimberly L. Blackwell, Pere Gascón, C.M. Jones, Allen Nixon, Andriy Krendyukov, Roumen Nakov, Y. Li, Nadia Harbeck> ;Annals of Oncology. 2017 Sep 1
Join now to see all

Lectures

Individualized Breast, GYN, and Colon Cancer Management; New Data and Updates Relevant to Patient Care
Mayo School of Continuous Professional Development, Jacksonville, Florida - 2/15/2013

Press Mentions

Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational UpdatesNovember 9th, 2022
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational UpdatesNovember 9th, 2022
Tempus Announces Open Enrollment for Study in Collaboration with GSK to Evaluate Niraparib in Advanced Solid Tumor Patients with PALB2 MutationsJanuary 13th, 2022
Join now to see all